Lead Product(s) : Naldemedine Tosylate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Announces Positive NICE Recommendation for Rizmoic® (naldemedine) for OIC
Details : Based on Phase 3 trial data, Rizmoic has been shown to increase the frequency of bowel movements compared to placebo in patients either with cancer or chronic non-cancer pain who had previously received laxative treatment.
Product Name : Rizmoic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : Naldemedine Tosylate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
